Hospital
Comanche County Hospital Authority
Comanche County Hospital Authority was paid $17.74M by Medicaid between Jan 2018 and Nov 2024, across 128 billing codes. Its largest line is 99283, emergency room visit (moderate) — 37% of everything it billed.
33Billing provider infoCOMANCHE COUNTY HOSPITAL AUTHORITY
LAWTON, OK 73502
LAWTON, OK 73502
33aNPI1720022379assigned 06/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.74M
24GClaims325,584
24DCodes billed128
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#7 of 75
Median peer was paid$3.66M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, BRENT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,545 | $1.37M | |
| 2019 | 39,418 | $1.73M | |
| 2020 | 35,274 | $1.44M | |
| 2021 | 46,576 | $2.35M | |
| 2022 | 67,069 | $4.19M | |
| 2023 | 73,153 | $4.48M | |
| 2024incomplete | 33,549 | $2.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 37% | 39,952 | 39,599 | $6.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 13,871 | 13,752 | $3.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 6,590 | 6,541 | $2.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 9,373 | 9,316 | $867K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 5,884 | 5,831 | $786K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.0% | 3,833 | 3,822 | $524K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 2,417 | 1,181 | $351K |
| 80053 | Comprehensive metabolic panel | 1.6% | 28,938 | 27,944 | $292K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 30,123 | 27,727 | $232K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 830 | 517 | $165K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 20,710 | 19,043 | $145K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,438 | 20,174 | $145K |
116 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,957 | $121K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,566 | $94K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,986 | $93K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,994 | $91K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,270 | $87K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,726 | $77K |
| 81003 | <1% | 19,092 | $72K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,540 | $65K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,763 | $56K |
| 11043 | <1% | 187 | $51K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 563 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 583 | $46K |
| 80061 | Lipid panel | <1% | 3,701 | $46K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 533 | $44K |
| 84439 | <1% | 5,751 | $43K | |
| 85027 | <1% | 6,836 | $40K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 740 | $39K |
| 87510 | <1% | 2,303 | $39K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,895 | $39K |
| 87660 | <1% | 2,278 | $39K | |
| 87480 | <1% | 2,303 | $39K | |
| S9443 | Lactation classes, non-physician provider, per session | <1% | 388 | $33K |
| 84703 | <1% | 4,785 | $32K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,902 | $32K |
| 86850 | <1% | 3,837 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,538 | $26K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 26 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 359 | $18K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 789 | $16K |
| 83615 | <1% | 2,449 | $13K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 393 | $12K |
| 86780 | <1% | 1,174 | $12K | |
| 86803 | <1% | 940 | $12K | |
| 82570 | <1% | 1,478 | $11K | |
| 81001 | <1% | 3,725 | $10K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 168 | $9K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 48 | $8K |
| 82731 | <1% | 144 | $8K | |
| 86762 | <1% | 638 | $8K | |
| 86787 | <1% | 701 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 248 | $7K |
| 84550 | <1% | 2,062 | $7K | |
| 82962 | <1% | 1,480 | $6K | |
| 76801 | <1% | 107 | $6K | |
| 87340 | <1% | 643 | $6K | |
| 83021 | <1% | 361 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 208 | $5K |
| 86592 | <1% | 1,379 | $5K | |
| 83690 | <1% | 875 | $5K | |
| 84156 | <1% | 1,545 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 131 | $4K |
| 82950 | <1% | 882 | $4K | |
| 87081 | <1% | 583 | $4K | |
| 84484 | <1% | 199 | $3K | |
| 86900 | <1% | 1,233 | $3K | |
| 80306 | <1% | 211 | $3K | |
| 86901 | <1% | 1,213 | $3K | |
| 87150 | <1% | 83 | $2K | |
| 82728 | <1% | 183 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 25 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14 | $2K |
| 80074 | <1% | 40 | $2K | |
| 83735 | <1% | 239 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 56 | $1K |
| 59025 | Fetal non-stress test | <1% | 219 | $1K |
| 87077 | <1% | 101 | $1K | |
| 96367 | <1% | 19 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $976.15 |
| 83550 | <1% | 132 | $963.48 | |
| 83540 | <1% | 155 | $754.20 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13 | $721.71 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $656.10 |
| 85652 | <1% | 301 | $592.80 | |
| 83605 | <1% | 56 | $564.24 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $492.57 |
| 88304 | <1% | 12 | $486.86 | |
| 84146 | <1% | 26 | $448.24 | |
| 83655 | <1% | 37 | $433.26 | |
| 86735 | <1% | 39 | $406.35 | |
| 86765 | <1% | 39 | $401.10 | |
| 85041 | <1% | 145 | $391.28 | |
| 85018 | <1% | 165 | $344.98 | |
| 85014 | <1% | 165 | $344.42 | |
| 86021 | <1% | 24 | $321.36 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 706 | $313.98 |
| 73562 | <1% | 12 | $312.16 | |
| 86038 | <1% | 29 | $311.75 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 41 | $277.55 |
| 86334 | <1% | 13 | $258.31 | |
| 87430 | <1% | 17 | $235.11 | |
| 82607 | <1% | 15 | $212.85 | |
| 82043 | <1% | 38 | $208.28 | |
| 86140 | <1% | 42 | $177.01 | |
| 82550 | <1% | 31 | $175.49 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 14 | $159.63 |
| 86430 | <1% | 28 | $152.88 | |
| 84165 | <1% | 14 | $133.70 | |
| 87186 | <1% | 14 | $115.35 | |
| 87070 | <1% | 13 | $110.76 | |
| 81015 | <1% | 39 | $105.69 | |
| 85610 | <1% | 26 | $95.50 | |
| 85045 | <1% | 27 | $54.99 | |
| 85651 | <1% | 12 | $45.60 | |
| 82947 | <1% | 13 | $45.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 38 | $39.68 |
| 86696 | <1% | 13 | $17.21 | |
| 86695 | <1% | 13 | $11.73 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 1,000 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 222 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 115 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 27 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 143 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 54 | $0.00 |
| J3490 | Unclassified drugs | 0% | 36 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 40 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, BRENT (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.